RJFSA
HEPA

Raymond James Financial Services Advisors’s Hepion Pharmaceuticals HEPA Stock Holding History

Raymond James Financial Services Advisors’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-18
Closed -$5.48K – 3324
2022
Q4 		$5.48K Buy
+18
New +$7.61K ﹤0.01% 3214
2018
Q2 		– Hold
0
– -$4K – 2816
2018
Q1 		– Hold
0
– – – 2540

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Envestnet Asset Management
Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Raymond James Financial Services Advisors's HEPA Position: Q1 2023 in Review

Raymond James Financial Services Advisors sold out of Hepion Pharmaceuticals (HEPA) in Q1 2023, closing a stake of 18 shares — an estimated $5.48K sold.

Raymond James Financial Services Advisors first reported a position in HEPA in Q4 2022 and held it in 1 quarter. The position peaked at $5.48K in Q4 2022. 26 funds tracked by Wall St. Rank hold HEPA as of Q1 2023.

  • Raymond James Financial Services Advisors reported no remaining Hepion Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 18 Hepion Pharmaceuticals shares in Q1 2023, an estimated $5.48K.
  • Raymond James Financial Services Advisors first reported a position in Hepion Pharmaceuticals in Q4 2022 and held it in 1 quarter.
  • Raymond James Financial Services Advisors's Hepion Pharmaceuticals position peaked at $5.48K in Q4 2022.
  • 26 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q1 2023, filed 14 Apr 2023.